Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen

Update: 2016-04-29

Description

Prof Ganz presents, at a press conference at SABCS 2015, about the analysis of patient-reported outcomes and the secondary endpoint of the phase III, NSABP B-35 clinical trial.

NSABP B-35 compares, anastrazole and tamoxifen in postmenopausal women with ductal carcinoma in-situ who underwent lumpectomy plus radiotherapy.

The data showed that there were no differences in outcomes related to quality of life but some differences in outcomes related to symptoms in the two treatment groups.

Comments

In Channel

Breast-conserving therapy yields better 10-year outcomes than mastectomy for early-stage patients

2016-04-2904:14

Interrupting breast cancer treatment for young women who desire pregnancy

2016-04-2909:30

Survival outcomes from the CALGB 40603 study in triple-negative breast cancer

2016-04-2908:54

TAILORx: Genomic test helps identify low-risk women who do not need chemotherapy

2016-04-2904:33

Homologous recombination deficiency predicts neo-adjuvant chemotherapy response in triple-negative breast cancer

2016-04-2906:08

Hormonal treatments produce similar quality of life outcomes in DCIS

2016-04-2907:56

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen

2016-04-2909:31

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen

2016-04-2911:36

Trastuzumab emtansine improves overall survival versus treatment of physician's choice

2016-04-2907:31

Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results

2016-04-2907:01

TH3RESA: T-DM1 improves overall survival in previously treated advanced cancer patients

2016-04-2905:23

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen

2016-04-2806:31

NSABP FB-7: Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancer

2016-04-2806:34

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival

2016-04-2808:18

Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients

2016-04-2807:01

Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3B

2016-04-2808:29

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation

2016-04-2809:22

Treating women with endocrine-resistant HR /HER2 advanced breast cancer

2016-04-2805:02

Molecular evolution of breast cancer during neoadjuvant chemotherapy

2016-04-2807:18

Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer

2016-04-2808:04

00:00

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen

Prof Patricia Ganz - UCLA, Los Angeles, USA

#box-pro-ellipsis-176331245532389{-webkit-line-clamp:2;}Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen

Prof Patricia Ganz - UCLA, Los Angeles, USA

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen